España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Nanoviricides
NNVC
AMEX
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$1.50
0.01
0.67%
At close: -
$1.74
0.24
16.00%
After Hours: 4:27 PM EDT
Get Report
Comment
Nanoviricides (NNVC) Forecast
News
Earnings
Nanoviricides (NNVC) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Nanoviricides (AMEX:NNVC) Stock
Nanoviricides Stock (AMEX: NNVC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, September 30, 2024
NanoViricides Advances NV-387 Antiviral Drug,...
Benzinga Newsdesk
Thursday, September 26, 2024
NanoViricides shares are trading higher after...
Benzinga Newsdesk
NanoViricides Secures First Rights To TheraCo...
Benzinga Newsdesk
Monday, August 26, 2024
NanoViricides Considers NV-387 for MPOX Treat...
Benzinga Newsdesk
Monday, August 19, 2024
NanoViricides' NV-387 Aims to Tackle RSV, COV...
Benzinga Newsdesk
Thursday, August 08, 2024
NanoViricides Provides An Update On Its Clini...
Benzinga Newsdesk
Thursday, July 11, 2024
NanoViricides shares are trading higher after...
Benzinga Newsdesk
NanoViricides Discusses Its Development Progr...
Benzinga Newsdesk
Thursday, June 20, 2024
NanoViricides shares are trading higher after...
Benzinga Newsdesk
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Nanoviricides Reports That The Ultra-broad-sp...
Benzinga Newsdesk
Friday, June 14, 2024
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Wednesday, June 12, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
Tuesday, June 11, 2024
NanoViricides' NV-387 Results Show Flat Blood...
Benzinga Newsdesk
Monday, June 10, 2024
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Wednesday, June 05, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
Tuesday, June 04, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
NanoViricides Reports On The Highly Desirable...
Benzinga Newsdesk
Monday, June 03, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Wednesday, May 29, 2024
NanoViricides Elaborates On Its Development O...
Benzinga Newsdesk
Thursday, May 16, 2024
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Wednesday, May 08, 2024
NanoViricides Reports Breakthrough in Treatin...
Benzinga Newsdesk
Tuesday, May 07, 2024
EF Hutton Reiterates Buy on Nanoviricides, Ma...
Benzinga Newsdesk
Monday, May 06, 2024
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
NanoViricides shares are trading higher after...
Benzinga Newsdesk
NanoViricides' Broad-Spectrum Antiviral NV-38...
Benzinga Newsdesk
Tuesday, April 30, 2024
NanoViricides Reports That The Phase I NV-387...
Benzinga Newsdesk
Friday, February 16, 2024
EF Hutton Reiterates Buy on Nanoviricides, Ma...
Benzinga Newsdesk
Thursday, February 15, 2024
Nanoviricides Q2 EPS $(0.18) Down From $(0.15...
Benzinga Newsdesk
Thursday, February 01, 2024
NanoViricides Explains That The Demonstration...
Benzinga Newsdesk
Wednesday, January 31, 2024
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
Meg Flippin
-
Sponsored
Monday, January 29, 2024
NanoViricides Says The Healthy Subjects Part ...
Benzinga Newsdesk
Monday, January 08, 2024
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
Kenneth Adams
Tuesday, November 28, 2023
NanoViricides Has Completed The Single-ascend...
Benzinga Newsdesk
Tuesday, September 26, 2023
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
David Willey
-
Sponsored
Monday, September 18, 2023
First Human Clinical Trials Of A Potentially "Game-Changing Broad Spectrum Antiviral" Are Progressing Successfully – Drug Could Treat COVID, RSV And Many Other Respiratory Viruses
Rachael Green
-
Sponsored
Tuesday, August 22, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Monday, August 21, 2023
NanoViricides shares are trading higher after...
Benzinga Newsdesk
Nanoviricides Reported That The Phase 1a/1b H...
Benzinga Newsdesk
Tuesday, July 18, 2023
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
David Willey
-
Sponsored
Tuesday, July 11, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Why Are NanoViricides Shares Gaining Today
Vandana Singh
NanoViricides shares are trading higher after...
Benzinga Newsdesk
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin
NanoViricides Reports Effectiveness Of Antivi...
Benzinga Newsdesk
Monday, July 10, 2023
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
David Willey
-
Sponsored
Thursday, July 06, 2023
NanoViricides Says Clinical Trial Of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well - NV-CoV-2 Is Positioned To Fulfill Many Unmet Medical Needs
Happy Mohamed
NanoViricides Says Clinical Trial Of Its Broa...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
